StemCells, Inc. (STEM) today announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer’s disease (AD). The research was conducted in collaboration with a world-renowned leader in AD, Frank LaFerla, Ph.D., Director of the University of California, Irvine (UCI) Institute for [...]
Anthera Pharmaceuticals (ANTH): Protecting Investment and Riding Free Shares

Anthera Pharmaceuticals, Inc. (ANTH) stock gained today 87.24% on 23.9M shares in volume. We profiled ANTH as a potential bounce candidate right after the company’s report of the mixed results for its Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus. Today Anthera Pharmaceuticals came out with the positive clinical data from the [...]
Hovnanian Enterprises (HOV) and GSO Capital Partners: $125 Million Arrangement

Hovnanian Enterprises, Inc. (NYSE:HOV) and GSO Capital Partners LP (“GSO”) announced today a land banking arrangement for up to $125 million. GSO, the credit arm of The Blackstone Group (NYSE:BX), will manage funds and acquire a portfolio of land parcels from Hovnanian and option finished lots on a quarterly takedown basis back to Hovnanian. As [...]
Misonix, Inc. (MSON): On Watch for the 52W High Breakout

Misonix, Inc. (MSON) announced today its participation in SpineWeek 2012, in Amsterdam, Netherlands. SpineWeek takes place every four years and synchronizes the annual meetings of leading scientific societies, focused on disorders of the spine. SpineWeek had an attendance of over 2,600 individuals, including many recognized leaders in the field from all around the globe. Misonix [...]
Ocean Power Technologies (OPTT): Teaming Agreement with Lockheed Martin (LMT)

Ocean Power Technologies, Inc. (OPTT) and Lockheed Martin (LMT) announced today that they have entered into a teaming agreement with the goal of developing a 19 megawatt wave-energy project in Victoria, Australia, one of the largest wave-energy projects announced to date. Lockheed Martin will assist with the design of Ocean Power Technologies’ (OPT) PowerBuoy® technology, [...]
ICPA, SCFR: Last-minute & After-Hours News

IC Places, Inc. (ICPA) announced today that it has entered into a distribution partnership with Smarter Comics, named “One of the 100 Most Brilliant Ideas of 2012″ by Entrepreneur Magazine in June 2012. Smarter Comics takes classic and modern Self Help Books and transforms them into a comic book format. The first Smarter Comics’s book offered [...]
WFR, ATPG, ANTH: Today’s Movers for Tomorrow’s Market

MEMC Electronic Materials, Inc. (WFR) announced today that four solar projects in Europe has been executed by company during the second quarter of 2012. Cash received on the closing of these transactions will be included in the company’s second quarter cash balances. MEMC Electronic Materials, Inc. 501 Pearl Drive (City of O’Fallon) St. Peters, MO [...]
Aeterna Zentaris Inc. (AEZS): Put it on Watch
Aeterna Zentaris Inc. (NASDAQ: AEZS) announced on June 28th that its Japanese partner Yakult Honsha (“Yakult”) (Tokyo: 2267) has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine, the Company’s oral Akt/PI3K inhibitor drug. Yakult, who are sponsoring and conducting this trial in Japan, reported that a first patient [...]
KB Home (KBH): Revenues Increased, Net Loss Narrows Significantly

KB Home (KBH) today reported results for its second quarter ended May 31, 2012. Highlights: Revenues totaled $302.9 million, up 11% from $271.7 million for the second quarter of 2011 Revenues up 24% in the West Coast region, 5% in the Southeast region, and 4% in the Central region for the three of the Company’s [...]
Idenix Pharmaceuticals, Inc. (IDIX): Follow the Money

Idenix Pharmaceuticals, Inc. (IDIX) yesterday after market close announced results from an ongoing phase IIb study of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV). Someone may be arguing about IDX184 efficacy judging by the number of trial patients that responded well to the initial treatment with a combination of IDX184, pegylated interferon, and [...]
